Adagene EBIT

The latest EBIT for ADAG is $-59M as of June 2026. That compares with $-46M in the prior-year period — down 29.0% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Adagene's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADAG's EBIT moved from $-46M to $-59M — a 29.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adagene's operating scale or balance-sheet position.

Against Healthcare companies, ADAG currently prints $-59M for EBIT, while the sector average sits near $110B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Adagene's growth, margins, and balance sheet.

A EBIT figure of $-59M for ADAG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting ADAG's EBIT ($-59M), review year-over-year change from $-46M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.